Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma-Reference-Cited by-同舟云学术

Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma

Published:2021-06-03 Issue:12 Volume:64 Page:8053-8075
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Perry Matthew W. D.¹^ORCID,Björhall Karin²,Bold Peter³,Brűlls Mikael⁴,Börjesson Ulf⁵,Carlsson Johan⁶,Chang Hui-Fang Amy¹,Chen Yunhua⁷,Eriksson Anders¹,Fihn Britt-Marie³,Fransson Rebecca⁸,Fredlund Linda⁶^ORCID,Ge Hongbin⁷,Huang Haijuan⁷,Karabelas Kostas⁹,Lamm Bergström Eva³,Lever Sarah¹,Lindmark Helena⁶,Mogemark Mickael¹,Nikitidis Antonios¹,Palmgren Anna-Pia¹,Pemberton Nils¹^ORCID,Petersen Jens¹⁰,Rodrigo Blomqvist Mio¹¹,Smith Reed W.¹,Thomas Matthew J.²,Ullah Victoria¹,Tyrchan Christian¹^ORCID,Wennberg Tiiu²,Westin Eriksson Annika¹²,Yang Wenzhen⁷^ORCID,Zhao Shuchun⁷,Öster Linda¹⁰

Affiliation:

1. Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

2. Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

3. DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

4. Early Product Development & Manufacturing, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

5. Computational Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

6. Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

7. Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China

8. Advanced Drug Delivery, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

9. Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

10. Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

11. Bioscience Cough and In Vivo, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

12. Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00434

Reference31 articles.

1. PI3K isoforms in cell signalling and vesicle trafficking

2. Homeostatic and pathogenic roles of PI3Kδ in the human immune system

3. Molecules in medicine mini-review: isoforms of PI3K in biology and disease

4. PIK3CA protein expression summary - The Human Protein Atlas; https://www.proteinatlas.org/ENSG00000121879-PIK3CA (accessed Nov 11, 2020).

5. PIK3CB protein expression summary - The Human Protein Atlas; https://www.proteinatlas.org/ENSG00000051382-PIK3CB (accessed Nov 11, 2020).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation;Journal of Medicinal Chemistry;2024-06-22

2. PI3Kγδ inhibition suppresses key disease features in a rat model of asthma;Respiratory Research;2024-04-23

3. An Intramolecular Diels–Alder Approach to the Isoindolinone Core of AZD8154;Organic Process Research & Development;2024-03-13

4. Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities;Expert Opinion on Drug Discovery;2024-02-26

5. Medicinal Polypharmacology in the Clinic – Translating the Polypharmacolome into Therapeutic Benefit;Pharmaceutical Research;2024-02-16